INTRODUCTION
Cardiovascular disease is one of the leading causes of death, especially in developed countries. Several risk factors for cardiovascular disease have now been well established, especially cigarette smoking, hypertension, lipid disorders, and diabetes mellitus. Pharmacotherapeutic interventions such as the use of aspirin and other antithrombotic drugs, antihypertensive drugs, and cholesterol-lowering therapy probably have contributed to the gradual decline in cardiovascular disease over the last decades (1,2). Statins are inhibitors of hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase, which inhibits cholesterol production in the hepatocyte. This increases the synthesis of low-density lipoprotein (LDL) receptors and thereby lowers cholesterol. In recent years, several landmark trials have been published that establish the efficacy of statin therapy in primary and secondary prevention (3-7). Treatment with statins over a 5-yr period was associated with a statistically significant reduction in mortality and in the number of patients experiencing a heart attack or a stroke, or undergoing a revascularization procedure. The risk reduction for coronary artery disease for subjects using statins was approx 30%. These reductions, however, are average effects for all patients included in the trials; in subpopulations these effects may differ.
Important factors in interpreting variability in the outcome of drug therapy include the patient's overall health, prognosis, disease severity, quality of drug prescribing, compliance with prescribed pharmacotherapy, and the genetic profile of the patient (8,9). In the large trials, several subgroups have been analyzed. In the Cholesterol and Recurrent Events (CARE) trial, the effect of pravastatin on the rates of major coronary events was greater among women (-46% [95% CI -22 to -62%]) than among men (-20% [95% CI -8 to -30%]) (3). In the other trials there were no significant differences between men and women. Other subgroup analyses included age groups; comorbidity such as hypertension, diabetes mellitus, previous myocardial infarction, and smoking; and pretreatment plasma lipid levels, but these yielded no statistically significant differences (3) (4) (5) (6) (7) 10, 11) . In the Scandinavian Simivastatin Survival study (4S), measurements of the serum cholestanol concentration revealed a subgroup of patients in whom coronary events were not reduced by simvastatin treatment. The reduction in relative risk increased gradually from 0.62 to 1.17 in the quarters of distribution of cholestanol at baseline. Thus, patients with high baseline synthesis of cholesterol seem to be responders whereas those with low synthesis of cholesterol are nonresponders (12).
PHARMACOGENETICS
Pharmacogenetics and pharmacogenomics are emerging disciplines that focus on genetic determinants of drug response at the levels of single genes or the entire human genome, respectively (13). Polymorphisms may influence drug response in three ways (14) . The first way is through pharmacokinetic interactions, caused by genetically based differences in drug absorption, disposition, metabolism and excretion. An important role is played by polymorphisms in the cytochrome P450 (CYP) enzymes. In addition, there are pharmacodynamic gene-drug interactions that involve gene products expressed as receptors or signal transduction molecules, which are relevant to the pharmacodynamics of drugs. After entering the circulation each drug interacts with numerous proteins and multiple types of receptors. These proteins determine the site of action and the pharmacological response. The third possibility of influencing drug response is through genes
